Westside Investment Management Inc. Buys 18,660 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Westside Investment Management Inc. boosted its stake in INmune Bio, Inc. (NASDAQ:INMB) by 26.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,975 shares of the company’s stock after purchasing an additional 18,660 shares during the period. Westside Investment Management Inc.’s holdings in INmune Bio were worth $420,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in INMB. Financial Advocates Investment Management increased its stake in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 2,000 shares during the period. Fermata Advisors LLC grew its holdings in INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after acquiring an additional 4,267 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of INmune Bio in the second quarter valued at about $121,000. Jane Street Group LLC purchased a new position in shares of INmune Bio in the third quarter valued at about $79,000. Finally, Sanctuary Advisors LLC bought a new position in shares of INmune Bio during the third quarter valued at about $113,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Trading Up 14.0 %

NASDAQ:INMB opened at $7.44 on Wednesday. The company has a 50-day moving average price of $5.14 and a 200-day moving average price of $6.06. The stock has a market cap of $165.05 million, a price-to-earnings ratio of -3.35 and a beta of 1.78. INmune Bio, Inc. has a 12 month low of $4.32 and a 12 month high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period last year, the firm posted ($0.48) EPS. Equities analysts forecast that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Alliance Global Partners started coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock. Raymond James started coverage on INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective on the stock.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.